Penwest Pharmaceuticals Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 2 Calls Today's Calls

Call Details Penwest Pharmaceuticals Earnings Conference Call (Q1 2008) Fri, May 2, 2008, 11:00 am Eastern Listen to the archived event audio About Penwest Pharmaceuticals (NasdaqGM:PPCO) Penwest Pharmaceuticals Co. develops pharmaceutical products based on drug delivery technologies with focus on products that address disorders of the nervous system. It offers Opana ER, an oral extended release opioid analgesic for patients with moderate to severe pain requiring continuous opioid treatment using its TIMERx drug delivery technology; and Nifedipine XL, for the treatment of hypertension and angina. The company’s product candidates in clinical development include Nalbuphine ER for the treatment of moderate chronic pain; A0001 for the treatment of diseases related to the mitochondrial respiratory chain. It also develops product candidates for the treatment of pain, epilepsy, and Parkinson’s disease. Penwest Pharmaceuticals Co. has a strategic alliance agreement with Endo Pharmaceuticals, Inc.; and a technology licensing collaborative agreement with Mylan Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. The company was founded in 1991 and is based Danbury, Connecticut. Penwest Pharmaceuticals Co. (NasdaqNM:PPCO) operates independently of Penford Corp. as of August 31, 1998. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings